Mohammad Alashqar Shares Fitusiran Review for Hemophilia A and B, With or Without Inhibitors
Mohammad Alashqar, Postdoctoral Pharmacotherapy Research Fellow at The Ohio State University College of Pharmacy, shared on LinkedIn:
”Grateful to share that my review paper, “Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors,” has been published online today (12/26)
Sincere thanks to everyone who supported me throughout this journey—especially Dr. Milap Nahata for his mentorship, guidance, and invaluable feedback.
This work would not have been possible without such support.
Looking forward to continuing contributions to hemophilia and thrombosis research.”
Read the full article here.
Article: Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors
Authors: Mohammad Alashqar, Milap Nahata
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026
-
Jul 13, 2026, 17:12Santagata Davide: A Great Session and an Incredible Opportunity to Present Our Research at ISTH 2026
-
Jul 13, 2026, 16:26Real-World Data Across Time Reveal Important Advances in Hemophilia Treatment – ATHN
-
Jul 13, 2026, 16:19Mary Cushman: Celebrating Our Incredible ISTH Council Members in Paris
-
Jul 13, 2026, 16:17Wolfgang Miesbach: Gene Therapy Shows Promising Early Results in Adolescents With Hemophilia B at ISTH 2026
-
Jul 13, 2026, 16:06Dino Mehic: Honored to Receive the ISTH Early Career Top Reviewer Awards
-
Jul 13, 2026, 16:01Advancing DIC Diagnosis in Cirrhosis Through Disease-Specific Risk Stratification – JTH
-
Jul 13, 2026, 15:52Joshua Muia: Presenting Our Research on ADAMTS13/VWF Dysregulation in Sepsis at ISTH 2026